Precision BioSciences announces presentation at WMS on PBGENE-DMD

Precision BioSciences (DTIL) announced a late-breaking poster presentation at the 30th Annual International Congress of the World Muscle Society, WMS, being held October 7-12, 2025, in Vienna, Austria. Abstract Title: Treatment with PBGENE-DMD results in durable improvements in muscle function over time through increased dystrophin expression and dystrophin-positive cells: Utilizing two ARCUS nucleases delivered by a single AAV, PBGENE-DMD demonstrated durable improvements in muscle function over time through increased dystrophin expression and dystrophin-positive cells. In a DMD mouse model, PBGENE-DMD was administered at doses up to 1×1014 vg/kg, and mice were evaluated at 3- and 9-months post-dosing for molecular and functional outcomes. Following treatment, dystrophin protein was detected in all muscles evaluated, with increased expression observed at 9 months versus prior timepoints in the quadriceps, gastrocnemius, heart, and diaphragm resulting in substantial and sustained functional muscle improvement. Precision continues to advance the final toxicology studies with an anticipated investigational new drug and/or clinical trial application filing targeted by the end of 2025 with initial clinical data expected in 2026.